Advertisement
Document › Details
Lonza Group AG. (9/18/23). "Press Release: Board Announcement. CEO Pierre-Alain Ruffieux to Leave Lonza – Albert M. Baehny to Step in as CEO ad interim". Basel.
Organisation | Lonza Group AG (SWX: LONN) | |
Today | Lonza (Group) | |
Group | Lonza (Group) | |
Product | contract manufacturing (biologicals) | |
Product 2 | contract manufacturing (drugs) | |
Person | Ruffieux, Pierre-Alain (Lonza 202011– CEO before Roche + Novartis + Serono) | |
Person 2 | Baehny, Albert M. (Lonza 202005 Board Chairman + interim CEO) | |
> Capital Markets Day on October 17 confirmed
Lonza announced today that Pierre-Alain Ruffieux, CEO, will leave the company at the end of September by mutual agreement. The Board of Directors also announced that Albert M. Baehny, Chairman, will take on the additional responsibility of Chief Executive Officer on an ad interim basis until a permanent successor is appointed.
The medium-term strategy and outlook will be discussed in detail at the Capital Markets Day in Visp on 17th October 2023.
Christoph Maeder, Lead Independent Director and Vice-Chairman, Lonza, said: “Albert has agreed to lead the Company as CEO on a temporary basis until a successor is in place, for which the Board thanks him. The search for a permanent CEO will start soon. The Board would like to thank Pierre-Alain for his service to Lonza and wishes him well in his future endeavors.”
Albert M. Baehny, Chairman, Lonza, said: “I am committed to Lonza, our employees and all stakeholders. While recent months have undoubtedly been challenging, the company is a global leader in our industry and has many opportunities for further growth across all our businesses. In the months ahead, I will ensure that we are optimally positioned to fully capture those opportunities and I look forward to working with my Board and Executive Committee colleagues.”
Record changed: 2024-01-20 |
Advertisement
More documents for Lonza (Group)
- [1] Lonza Group AG. (4/2/24). "Press Release: Wolfgang Wienand, Currently CEO of Swiss CDMO Siegfried Holding AG, Will Become Chief Executive Officer of Lonza in the Summer of 2024". Basel....
- [2] Lonza Group AG. (3/20/24). "Press Release: Lonza Signs Agreement to Acquire Large-scale Biologics Site in Vacaville (US) from Roche". Basel....
- [3] Cellbox Solutions GmbH. (11/1/23). "Press Release: Dr. Hartmut Tintrup Joins Cellbox Solutions GmbH as new CEO". Cologne....
- [4] PolyPeptide Group AG. (8/15/23). "Press Release: Transformational Progress Taking Shape, Profitability Impacted by Rapid Expansion – Appointment of Marc Augustin as New CFO". Baar....
- [5] Lonza Group Ltd.. (6/1/23). "Press Release: Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering". Basel & Amsterdam....
- [6] Synaffix B.V.. (1/5/23). "Press Release: Synaffix Enters License Agreement with Amgen to Build Next Generation ADCs". Amsterdam....
- [7] Synaffix B.V.. (1/4/23). "Press Release: Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate (ADC) Program". Amsterdam, San Francisco, CA, et al.....
- [8] Emergence Therapeutics AG. (9/6/22). "Press Release: Emergence Therapeutics Licenses Synaffix ADC Technology Platform in $360M Deal". Amsterdam & Duisburg....
- [9] Rentschler Biopharma SE. (8/18/22). "Press Release: Rentschler Biopharma Appoints Mark Caswell as Vice President, Site Head for US Facility". Laupheim & Milford, MA....
- [10] Merck KGaA. (4/5/22). "Press Release: Merck Advances BioProcessing Capabilities with Acquisition of MAST Platform from Lonza, a Leading Automated Bioreactor Sampling System". Darmstadt....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top